This podcast, part 2 of a 3-part series on thyroid eye disease (TED), provides an in-depth discussion on current medical and surgical options for TED and emerging therapies. Experts will review clinical data on teprotumumab, the only US Food and Drug Administration approved agent for TED and introduce clinical data on other treatments such as glucocorticoids, orbital radiation, rituximab, and tocilizumab. Listeners will learn how to select appropriate therapies across a spectrum of disease activity and duration.
- Provider:MedEdicus, LLC
- Activity Link: https://courses.mededicus.com/content/thyroid-eye-disease-conversations-comprehensive-comanagement-%E2%80%93-treatment-cecme-podcast#group-tabs-node-course-default1
- Start Date: 2025-01-15 06:00:00
- End Date: 2025-01-15 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Amgen, Inc. - Amount: 52217.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Limited
Subscribe
Login
0 Comments
Oldest